Therapeutic Vaccination in Lung Cancer: Past Attempts, Current Approaches and Future Promises

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• Lung cancer necessitates novel treatments beyond current immunotherapies like immune checkpoint blockade (ICB).
• ICB has improved outcomes but benefits are not universal, highlighting the need for complementary strategies.
• Therapeutic vaccines offer a potential avenue to enhance anti-tumor T cell responses.

Purpose of the Study:

• To review the rationale and mechanisms of therapeutic lung cancer vaccines.
• To critically analyze past and current vaccine development efforts in lung cancer.
• To discuss future directions for lung cancer vaccinology.

Main Methods:

• Literature review of preclinical and clinical studies on lung cancer vaccines.
• Analysis of immunological responses and clinical outcomes from vaccine trials.
• Examination of the historical progression and future potential of lung cancer vaccines.

Main Results:

• Early-phase clinical trials demonstrate the safety and immunogenicity of lung cancer vaccines.
• Vaccines have shown potential in generating antigen-specific T cell responses and some patient benefits.
• Widespread clinical success in large-scale trials is yet to be established.

Conclusions:

• Therapeutic lung cancer vaccines hold promise as a complementary strategy to existing immunotherapies.
• Further research and clinical validation are crucial for the successful integration of vaccines into lung cancer treatment.
• Advancing lung cancer vaccinology requires understanding mechanisms and overcoming past limitations.